Ophthotech Corp (NASDAQ:OPHT) To Develop Therapies To Help Deal With Multiple Orphan Ophthalmic Complications

The treatment of multiple orphan ophthalmic complexities for many years has been a matter that has eluded the knowledge of most of the top medical experts. However, Ophthotech Corp (NASDAQ:OPHT) has expressed that it is currently pursuing a very crucial strategy towards helping the ailing persons globally. It hopes that soon it will succeed at […]

Ophthotech Corp (NASDAQ:OPHT) Reaches Deal With Novartis AG (ADR) (NYSE:NVS) On Fovista

Boston, MA 05/20/2014 (wallstreetpr) – Developer of novel therapeutics, Ophthotech Corp (NASDAQ:OPHT) announced that it has struck a deal with the German-based Novartis AG (ADR) (NYSE:NVS) on licensing and commercialization of drug, Fovista, outside the U.S. Deal on Fovista The agreement struck between the two companies allows Ophthotech to grant exclusive rights to Novartis to commercialize […]

Ophthotech Corp (NASDAQ:OPHT) Suffers wider Loss In Q1

Boston, MA 05/20/2014 (wallstreetpr) – Ophthotech Corp (NASDAQ:OPHT), a developer of novel therapeutics, announced that it suffered a wider net loss for the first quarter. However, the loss per share is smaller than the analysts’ expectations for the same period. 1Q Results The company reported a net loss of $20.68 million or a loss of 64 […]